Pre-Transplant Total Lymphocyte Count Determines Anti-Thymocyte Globulin Exposure, Modifying Graft-versus-Host Disease Incidence and Post-Transplant Thymic Restoration: A Single-Center Retrospective Study

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Jan 21

PMID 36675660

Authors

Antonio Giacomo Grasso

Roberto Simeone

Alessandra Maestro

Davide Zanon

Natalia Maximova

Affiliations

Soon will be listed here.

Abstract

The use of anti-thymocyte globulin (ATG) as part of conditioning to prevent graft-versus-host disease (GVHD) may severely impair immune reconstitution (IR). We analyzed relationships between ATG exposure, the recipient lymphocyte count, IR, and transplant outcome. We retrospectively reviewed patients aged ≤ 18 years who underwent allogeneic HSCT between April 2005 and April 2020. The outcomes of interest included the incidence of GVHD, overall survival (OS), and IR. IR was analyzed through thymic magnetic resonance imaging (MRI) and by quantifying T CD4+ and recent thymic emigrants (RTEs). The ATG-exposed group was split into a low ATG/lymphocyte ratio subgroup (ratio < 0.01) and a high ATG/lymphocyte ratio subgroup (ratio > 0.01). The low ratio subgroup had a higher incidence of GVHD (29 [59%] vs. 7 [16.6%]) but a better IR in both laboratory and MRI imaging assessments (p < 0.0001). The median thymic volume in the low ratio subgroup was significantly higher (14.7 cm3 vs. 4.5 cm3, p < 0.001). This was associated with a better OS and lower transplant-related mortality (TRM) (80.4% vs. 58.0%, p = 0.031) and (13.1% vs. 33.0%, p = 0.035). An individualized approach to ATG dosing allows for the obtainment of rapid thymic reconstitution and the best transplant-related outcomes.

Citing Articles

Characteristics of Coronavirus Disease in Allogeneic Hematopoietic Stem Cell Transplantation During the Omicron Wave: A Single-Center Study.

Zhu P, Yang L, Liu L, Lai X, Shi J, Zhao Y Open Forum Infect Dis. 2024; 11(3):ofae038.

PMID: 38481430 PMC: 10932942. DOI: 10.1093/ofid/ofae038.

Impact of the Recipient's Pre-Treatment Blood Lymphocyte Count on Intended and Unintended Effects of Anti-T-Lymphocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation.

Nikoloudis A, Buxhofer-Ausch V, Aichinger C, Binder M, Hasengruber P, Kaynak E Cells. 2023; 12(14).

PMID: 37508496 PMC: 10378354. DOI: 10.3390/cells12141831.

References

Podgorny P, Ugarte-Torres A, Liu Y, Williamson T, Russell J, Storek J . High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder. Biol Blood Marrow Transplant. 2010; 16(7):915-26. DOI: 10.1016/j.bbmt.2010.02.027. View

Jamani K, Russell J, Daly A, Stewart D, Savoie L, Duggan P . Prognosis of grade 3-4 acute GVHD continues to be dismal. Bone Marrow Transplant. 2013; 48(10):1359-61. DOI: 10.1038/bmt.2013.59. View

Finke J, Bethge W, Schmoor C, Ottinger H, Stelljes M, Zander A . Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009; 10(9):855-64. DOI: 10.1016/S1470-2045(09)70225-6. View

Jamil M, Mineishi S . State-of-the-art acute and chronic GVHD treatment. Int J Hematol. 2015; 101(5):452-66. DOI: 10.1007/s12185-015-1785-1. View

Zaucha-Prazmo A, Gozdzik J, Debski R, Drabko K, Sadurska E, Kowalczyk J . Transplant-related mortality and survival in children with malignancies treated with allogeneic hematopoietic stem cell transplantation. A multicenter analysis. Pediatr Transplant. 2018; 22(3):e13158. DOI: 10.1111/petr.13158. View

Admiraal R, Lindemans C, van Kesteren C, Bierings M, Versluijs A, Nierkens S . Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. Blood. 2016; 128(23):2734-2741. DOI: 10.1182/blood-2016-06-721936. View

Admiraal R, van Kesteren C, Jol-van der Zijde C, Van Tol M, Bartelink I, Bredius R . Population pharmacokinetic modeling of Thymoglobulin(®) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing. Clin Pharmacokinet. 2014; 54(4):435-46. DOI: 10.1007/s40262-014-0214-6. View

Seidel M, Fritsch G, Matthes-Martin S, Lawitschka A, Lion T, Potschger U . Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol. 2005; 27(10):532-6. DOI: 10.1097/01.mph.0000184575.00717.25. View

Bryant A, Mallick R, Huebsch L, Allan D, Atkins H, Anstee G . Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017; 23(12):2096-2101. DOI: 10.1016/j.bbmt.2017.08.007. View

10.

Kennedy V, Chen H, Savani B, Greer J, Kassim A, Engelhardt B . Optimizing Antithymocyte Globulin Dosing for Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Based on Recipient Absolute Lymphocyte Count. Biol Blood Marrow Transplant. 2017; 24(1):150-155. DOI: 10.1016/j.bbmt.2017.08.029. View

11.

Scordo M, Bhatt V, Hilden P, Smith M, Thoren K, Cho C . Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34 Selected Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019; 25(8):1526-1535. PMC: 7302932. DOI: 10.1016/j.bbmt.2019.02.021. View

12.

Jamani K, Dabas R, Kangarloo S, Prokopishyn N, Luider J, Dharmani-Khan P . Rabbit Antithymocyte Globulin Serum Levels: Factors Impacting the Levels and Clinical Outcomes Impacted by the Levels. Biol Blood Marrow Transplant. 2018; 25(4):639-647. DOI: 10.1016/j.bbmt.2018.12.065. View

13.

Armand P, Kim H, Logan B, Wang Z, Alyea E, Kalaycio M . Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014; 123(23):3664-71. PMC: 4047501. DOI: 10.1182/blood-2014-01-552984. View

14.

Call S, Kasow K, Barfield R, Madden R, Leung W, Horwitz E . Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 2009; 15(2):274-8. PMC: 4776329. DOI: 10.1016/j.bbmt.2008.11.027. View

15.

Theurich S, Fischmann H, Chakupurakal G, Shimabukuro-Vornhagen A, Chemnitz J, Holtick U . Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis-A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2013; 88(1):178-86. DOI: 10.1016/j.critrevonc.2013.03.009. View

16.

Locatelli F, Bernardo M, Bertaina A, Rognoni C, Comoli P, Rovelli A . Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017; 18(8):1126-1136. DOI: 10.1016/S1470-2045(17)30417-5. View

17.

Ferrara J, Levine J, Reddy P, Holler E . Graft-versus-host disease. Lancet. 2009; 373(9674):1550-61. PMC: 2735047. DOI: 10.1016/S0140-6736(09)60237-3. View

18.

Toubert A, Glauzy S, Douay C, Clave E . Thymus and immune reconstitution after allogeneic hematopoietic stem cell transplantation in humans: never say never again. Tissue Antigens. 2012; 79(2):83-9. DOI: 10.1111/j.1399-0039.2011.01820.x. View

19.

Soiffer R, Kim H, McGuirk J, Horwitz M, Johnston L, Patnaik M . Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell.... J Clin Oncol. 2017; 35(36):4003-4011. PMC: 8462523. DOI: 10.1200/JCO.2017.75.8177. View

20.

Bosch M, Dhadda M, Hoegh-Petersen M, Liu Y, Hagel L, Podgorny P . Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy. 2012; 14(10):1258-75. PMC: 3681879. DOI: 10.3109/14653249.2012.715243. View